

ASX ANNOUNCEMENT

Not for release to US wire services or distribution in the United States

Oneview Healthcare PLC: Results of Security Purchase Plan

16 April 2026 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (**Oneview or the Company**), a global healthcare technology company, today announces the results of its security purchase plan (SPP) which closed on Friday, 10 April 2026.

The SPP was conducted in conjunction with Oneview's A\$19 million two-tranche placement to institutional and professional investors announced on 16 March 2026 (**Placement**).

Under the SPP, eligible securityholders could apply for up to A\$30,000 of new CHESSE Depository Interests over fully paid ordinary shares in Oneview (**New CDIs**) at the issue price of A\$0.19 per New CDI, being the same issue price as under the Placement.

The Oneview Board confirms that the Company received valid applications for 1,644,708 New CDIs (totalling approximately A\$0.3 million) under the SPP. As the total applications received were below the amount offered under the SPP of up to A\$2 million, all valid applications will be accepted in full. The New CDIs issued under the SPP are expected to commence trading on ASX on Monday, 20 April 2026, and will rank equally with existing Oneview CDIs on issue.

The total funds raised to date, comprising tranche 1 of the Placement (A\$12 million) and the SPP (approximately A\$0.3 million), amount to approximately A\$12.3 million (before costs).

As previously announced, tranche 2 of the Placement is subject to shareholder approval. The Company now expects that this approval will be sought at its annual general meeting, expected to be held in September 2026, rather than at an extraordinary general meeting in May 2026, in order to streamline governance processes and reduce costs. Tranche 2 of the Placement is expected to raise a further A\$7 million.

Proceeds raised under the Placement and SPP will be used to strengthen the balance sheet as deployments continue across new and existing customers, converting this signed pipeline into live, revenue-generating endpoints. Funds will also support the advancement of the new AI-powered virtual patient assistant, Ovie, as well as enabling the continued improvement of the AI software development life cycle and other automation and AI initiatives to drive business efficiency. Major US health systems place significant emphasis on balance sheet strength as part of their vendor evaluation process which is increasingly important as the Company scales in its core market.

MST Financial Services Pty Limited acted as Lead Manager and bookrunner to the Placement.

Securityholder enquiries

If you have any questions in relation to the SPP Offer, please contact the Oneview SPP Information Line on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.00pm (Sydney, Australia time) Monday to Friday.

Authorisation

This release has been approved by the Board of Directors of Oneview Healthcare plc.

About Oneview Healthcare plc

Serving hospitals and healthcare systems, academic medical centers, and paediatric hospitals worldwide, Oneview Healthcare's Care Experience Platform (CXP) provides a unified set of digital tools in a single bedside solution. Oneview's CXP connects patients, families and care teams with services, education, and information during hospital stays. Fully automated, integrated, and personalized, hospitals using Oneview positively impact safe and timely discharges while streamlining nursing workflows.

Enquiries:

James Fitter, CEO jfitter@oneviewhealthcare.com

Darragh Lyons, CFO dlyons@oneviewhealthcare.com

Website : www.oneviewhealthcare.com

Important Notices

This announcement is not a prospectus, disclosure document or other offering document under Australian law or under any other law. It is provided for information purposes and is not an invitation nor offer of securities or recommendation for subscription, purchase or sale in any jurisdiction. This announcement does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. It should be read in conjunction with, and full review made of, the Company's disclosures and releases lodged with ASX and available at www.asx.com.au. Each recipient must make its own independent assessment of the Company before acquiring any securities in the Company.

Forward Looking Statements

This announcement contains certain forward-looking statements. These forward-looking statements are based on the Company's expectations and beliefs concerning future events. Forward looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements

may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of the Company's business strategies. The success of any of those strategies will be realised in the period for which the forward looking statement may have been prepared or otherwise. Readers are strongly cautioned not to place undue reliance on forward-looking statements. The Company makes no undertaking to subsequently update or revise the forward-looking statements made in this announcement, to reflect the circumstances or events after the date of this announcement.

Not an offer of securities

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

For personal use only